Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Ian Davis envisages the evolution of prostate cancer care

Ian Davis • 3 Jun 2019
ASCO 2019
Genitourinary Cancer Prostate Cancer

Ian Davis, MB BS, PhD, FRACP, FAChPM, of the Monash University Eastern Health Clinical School, Melbourne, Australia, discusses the ways he believes the prostate cancer field will grow and evolve. Speaking at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL, Prof. Davis specifically mentions the benefit of combination of therapies.

More from Ian Davis

2:39
Pushing the boundaries in prostate cancer imaging
Ian Davis • 3 Jun 2019
5:16
ENZAMET: Enzalutamide for metastatic prostate cancer
Ian Davis • 3 Jun 2019
3:13
Prostate cancer: treatment sequencing and choice
Ian Davis • 3 Jun 2019
1:55
ARCHES trial overview: ADT plus enzalutamide for metastatic hormone-sensitive prostate cancer
Ian Davis • 6 Mar 2019

Related Videos

0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
0:38
Emerging combinatory immunotherapies show promise for mCRPC
Hannah McManus • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals